Navigation Links
One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective
Date:3/2/2011

RICHMOND, Va., March 2, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that the one-for-10 reverse stock split of Insmed's Common Stock became effective as of 5:00 PM EST, on March 2, 2011, after the State Corporation Commission of the Commonwealth of Virginia accepted the amendment to Insmed's Articles of Incorporation to effect the reverse stock split.  The shareholders of Insmed approved the amendment at the Special Meeting of Shareholders held on March 1, 2011.  Insmed's common stock will start trading on a split-adjusted basis on or about market open on March 3, 2011.

Following the reverse stock split, each holder of 10 shares of Insmed Common Stock immediately prior to the effectiveness of the reverse stock split became the holder of one share of Insmed Common Stock.  Shareholders will receive a cash payment in lieu of any fractional shares of Common Stock they are entitled to receive.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with unmet medical need. Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to expectations regarding the anticipated benefits of the reverse stock split and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  The risks and uncertainties include, without limitation, we may be unsuccessful in developing our product candidates, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2009 and Quarterly Report on Form 10-Q for the fiscal quarters ended March 31, 2010, June 30, 2010 and September 30, 2010.  Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
2. Lotus Pharmaceuticals Announces Approval of Reverse Stock Split
3. Heska Corporation Announces Stockholder Approval of Reverse Split
4. U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly
5. Bionovo Announces Reverse Stock Split
6. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
7. NOVT Corporation Completes Reverse/Forward Stock Split
8. CardioGenics Announces Reverse Stock Split
9. China Yongxin Pharmaceuticals Announces 1-for-12 Reverse Stock Split
10. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today
11. Otix Global, Inc. Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 2017  StatLab Medical Products ("StatLab" or ... of diagnostic supplies for the anatomic pathology ... Company LP ("Cressey & Company"), a healthcare-focused ... investment in the Company. Cressey & Company ... selling shareholder, Prairie Capital, L.P., with certain ...
(Date:6/7/2017)... 2017  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, ... Iowa location. The ... features an ISO 7 cleanroom—the standard needed to compound intravenous (IV) ... level of pollutants. "Our new ... better serve our Iowa patients," said ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology:
(Date:6/23/2017)... VA (PRWEB) , ... June 23, 2017 , ... ... of what is needed and will ultimately do significant harm to people with ... to everyone. , "While it leaves in place the Affordable Care Act ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and ... of visual loss in these patients. , But how often do ophthalmologists and optometrists ... to patients at risk of or with early symptoms of AMD? A study ...
(Date:6/23/2017)... ... 2017 , ... Military Connection friend and veteran advocate Micaela Bensko ... Atlantic lounge. , Bensko is no stranger to the plight of the disabled. ... life to supporting our wounded veterans. A world-class photographer, her riveting photos “The Wounds ...
(Date:6/23/2017)... ... 2017 , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique ... a proprietary technique that he calls the AuraLyft Facelift. The AuraLyft does ... patients can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South Asia ... 21 leaders from government, business and civil society in 11 countries across the Middle ... fall, engaging in a transformative exchange of knowledge and ideas with the leading minds ...
Breaking Medicine News(10 mins):